clade b recombinant, oligomeric gp140/mf59 adjuvant
Vaccineexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 18, 2003 (NCT00073216)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- clade b recombinant, oligomeric gp140/mf59 adjuvant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00073216 | Phase 1 | Nov 18, 2003 | Brown University, National Institute of Allergy and Infectious Diseases (NIAID), Vanderbilt University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Brown University | Academic/Hospital | 1 | 0 | 1 | 2003 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 2003 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2003 |
3 organizations
Page 1 / 1